| Description | ALLM (Calpain inhibitor II), a potent calpain and cathepsin protease inhibitor, not only prevents neuronal cell death but also enhances chronic neurological function following spinal cord injury (SCI)[1][2]. |
| In vivo | ALLM (Calpain inhibitor II) (0.5 mg/kg) is injected every 24 h for 5 days after SCI and inhibits the activation of calpain but not that of caspase 3. ALLM (0.05-2.5 mg/kg; i.p.; every 24 h for 1 week) reduces motor disturbances after spinal cord injury (SCI)[2]. ALLM prevents this neuronal cell death[2]. |
| Synonyms | Calpain inhibitor II |
| molecular weight | 401.56 |
| Molecular formula | C19H35N3O4S |
| CAS | 110115-07-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Stangl V, et al. Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J. 2004 Feb;18(2):272-9. 2. Arataki S, et al. Calpain inhibitors prevent neuronal cell death and ameliorate motor disturbances after compression-induced spinal cord injury in rats. J Neurotrauma. 2005 Mar;22(3):398-406. |